Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer

(2014) I. Cristobal et al.   CLINICAL CANCER RESEARCH

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma

(2014) Daisuke Kubota et al.   JOURNAL OF PROTEOME RESEARCH

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

VZV encephalitis that developed in an immunized patient during fingolimod therapy

(2014) N. P. Issa et al.   NEUROLOGY

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

(2014) M. Janghorban et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

(2014) H-C Yu et al.   Cell Death & Disease

Surface plasmon resonance spectroscopy for characterisation of membrane protein–ligand interactions and its potential for drug discovery

(2013) Simon G. Patching   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

(2013) Wei-Tien Tai et al.   HEPATOLOGY

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

(2012) Hui-Chuan Yu et al.   BIOCHEMICAL PHARMACOLOGY

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

(2012) Kuen-Feng Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Fingolimod for Multiple Sclerosis

(2012) Daniel Pelletier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

(2011) Davide Torti et al.   EMBO Molecular Medicine

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET

(2011) Lisette Arnaud et al.   FEBS LETTERS

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

(2011) D. J. Christensen et al.   JOURNAL OF IMMUNOLOGY

Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

(2011) K.-F. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling

(2011) Andréia M. Leopoldino et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

I2PP2A regulates p53 and Akt correlatively and leads the neurons to abort apoptosis

(2010) Gong-Ping Liu et al.   NEUROBIOLOGY OF AGING

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

(2010) K-F Chen et al.   ONCOGENE

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

(2008) Amancio Carnero et al.   CURRENT CANCER DRUG TARGETS

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

(2007) Melissa R. Junttila et al.   FASEB JOURNAL